NEW YORK (Reuters Health) – The risk of developing ulcerative colitis and Crohn’s disease is associated with iron levels in drinking water, according to a study in Norway.…
NEW YORK (Reuters Health) – An infusion of dexamethasone-loaded autologous erythrocytes appears to be an effective treatment for mild-to-moderate ulcerative colitis that is refractory to mesalamine, new research…
NEW YORK (Reuters Health) – Detection of JC virus, an important cause of progressive multifocal leukoencephalopathy (PML) in immunosuppressed patients, is not a good predictor of PML risk…
NEW YORK (Reuters Health) – Gastric acid suppression by proton pump inhibitors (PPIs) is associated with an increased risk of Clostridium difficile-related diarrhea in hospitalized patients, results of…
NEW YORK (Reuters Health) – Men who gain weight during adulthood – even those who are not considered to be overweight according to their body mass index –…
NEW YORK (Reuters Health) – The diagnosis of colorectal cancer will be delayed or missed in a substantial number of patients with inflammatory bowel disease (IBD) if colonoscopic…
NEW YORK (Reuters Health) – Children who develop Crohn’s disease before the age of five years have a less complicated disease course than children with disease onset after…
Partnership to Fight Chronic Disease is a national coalition of patients, providers, community organizations, business and labor groups and health policy experts, committed to raising awareness of policies…
A 50-week, placebo-controlled trial shows that combining infliximab and methotrexate provides no extra benefit in treating Crohn’s disease. References and Resources Feagan B. A randomized trial of methotrexate…
The FDA has approved natalizumab (Tysabri) for the treatment of moderate-to-severe Crohn’s disease in patients with evidence of inflammation who have had an inadequate response to, or are…